Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
CBYL, $0.77, Merger coming and the combined company shares are set to $18 to $20. The insiders and funds/institutional bought 2.7 Million shares in 2016 and they're holding 90% of the total O/S .
CBYL, IPO at $5 in Apr, 2015 and went high as $9.
Might be a big winner this year.
Conference Call
Friday, June 24th at 8:00 a.m. Eastern Time (5:00 a.m. Pacific Time)
KalVista and Carbylan will host a teleconference to discuss the proposed transaction announced on June 24, 2016.
The live call may be accessed by phone by calling (866)-405-1247 (domestic) or (201)-689-8045 (international).
Audio may also be accessed on the Carbylan website in the investor relations section at www.Carbylan.com, or the KalVista website at www.KalVista.com.
A replay of the call will be available for 14 days by phone by calling (877)-660-6853 (domestic) or (201)-612-7415 (international), conference ID 13639956.
GL
G
.80 is proving to be stubborn resistance on this trip back north. We need to break through and hold.
They haven't set a date/time. Just said "week of the 20th". Expect a PR tomorrow if not Monday with more info.
GL
G
If I may ask, what is the date of the conference call? Thank you in advance.
I stand corrected.
First of all, the proposal was put forth because the stock is below $1/share and to gain compliance, it needs to be higher. That was solved, up until the merger.
Secondly, there's no reason a reverse split should cause the price to fall. This is not a stinky pinkie where they're doing it so they can dilute further. It may (or may not) be necessary to complete the merger.
But my point remains valid - any merger, where the public company hands 80% of it's cash to another entity, causing the public company's stock to crash, is going to become a target for many law firms who salivate at this sort of bad deal.
Honestly, it makes no difference to me if you want to say it's a good deal, but the reverse split is what makes it bad. I don't care what the reason is. At the end of the day, they're taking a company with a cash liquidation value of somewhere around $1.50 and selling that cash at an 80% discount. The existing company and facilities are being shut down. The new entity is buying nothing but cash and a ticker, and they're stealing it.
Why anyone, from the board to the majority holders would agree to this is beyond me.
I still think the deal for the merger is fine. It is the Reverse split buried in the 8k that will kill the common shareholders.
I agree. If it doesn't make sense, there's more than we currently know or don't know.
I find it hard to believe that InterWest, Alta and Vivo are supporting this. There has to be more to the story...
Lawsuits aren't for illegal activity. They're for dereliction of fiduciary responsibility or fraud.
If you look at the class action shareholder actions over the last few years regarding takeovers, they occur when the price rise isn't great enough.
When the price falls 40% and they sell a company with $40 million in cash for no money while giving the new company shareholders 80% of the new entity, I think you might find there are a few folks who feel there was some double dealing.
We'll see.
Lawsuits based on what? Where do you see illegal activity?
If this deal goes ahead, I expect massive lawsuits.
There will be a conference call next week. Here's to hoping they have a good explanation.
On the surface, this deal looks very fishy...
Currently, CBYL is nothing more than $40m and a ticker.
How is KV "purchasing shares" such that they will own 80% and we are then $40m with a weak preclinical pipeline that will quickly draw down that cash?
I'm missing something, right?
The company needs to follow up in some meaningful manner. I have never seen a more irrational sell-off than this one.
* * $CBYL Video Chart 06-15-16 * *
Link to Video - click here to watch the technical chart video
LOL, or not.
It could happen, but with the stock now about 30% below it's cash liquidation value, I have to hope the majority shareholders aren't that stupid.
I hope so. I am still holding a handful of these hoping I missed something that makes them more valuable than they appear. I did read that the "majority" has "entered into agreements in support of the transaction" whatever that is worth...
GL
G
That may change since the proxy notice hasn't even been sent and the closing is subject to a vote.
"Consummation of the Transaction is subject to certain closing conditions, including, among other things, approval by the stockholders of Carbylan of the transactions contemplated by the Share Purchase Agreement and related matters"
Unfortunately a majority have already pledged support for the deal.
GL
G
The market isn't that stupid. It's a terrible deal. Selling 80% of $40 million plus in cash for some future prospects.
But the deal needs to be voted on and hopefully gets voted down.
Liquidate the company - stockholders would do better, only senior execs lose out as they can't keep their jobs.
CBYL insiders held about 50% of the OS which had a net cash value of about 43 million. Let's call that 40 million so the insiders shares are worth about 20 million cash. they choose to dilute their holdings to be about 10% of the OS. To me that means they believe the overall value of the new company structure would have to be worth at least $200 million. Likely a lot more long term or why take the risk
That is true that the 81-19% is on a fully-diluted basis. 100m authorized and 26m OS.
What I want to know is what they are bringing to the table given existing stockholder equity is something like $40m.
I keep seeing people saying "we only get 19%". Not true we as a stockholder own stock in the combined assets of the deal. the 19 vs 81% is that the insiders of Kalvista will own 81% of the outstanding shares. just like you own a certain % of shares. Now this probably means that the OS will go up to allow for Kalvista insiders to obtain 81%, but as insiders it isn't a big deal as they aren't going to sell them off anytime soon.
from 8k
On June 15, 2016, Carbylan Therapeutics, Inc. (“Carbylan”), KalVista Pharmaceuticals Ltd., a private company limited by shares incorporated and registered in England and Wales (“Kalvista”), the shareholders of KalVista (each a “Seller” and collectively, the “Sellers”)
The Sellers own 100% of the outstanding KalVista Shares and following the consummation of the Transaction, KalVista will become a wholly owned subsidiary of Carbylan.
Boy did I screw that trade up...
What a crappy deal! CBYL had $40m cash in the last Q. It looks like they agreed to something stupid like sell $40m cash and a ticker for $10m! Wtf...
Market doesn't seem to think too much of the deal.
At the last filing, CBYL had about $1.65 in cash/share and the PPS is now $1.20.
Not a good sign.
Hopefully the deal will be voted down as liquidation would be worth much more.
A year ago, VCs put $33 million into KalVista for an unspecified ownership percentage.
Now CBYL is putting in that amount, or more and we get 19% or less.
So it all depends on what the valuation of KalVista is these days.
Really hard to guess since CBYL looks like it already has the cash that the combined companies end up with, except now CBYL shareholders have 20% of the cash claim, instead of 100%.
The real question is the value of the KalVista drugs in the Pipeline.
Nasdaq compliance PR should be coming out at any time after achieving such on Friday.
$CBYL looking good
We're on the move again.
Hope your right sir
Level 2 there's nice support at 1.25 with bid volume stronger than ask
Shorts just keep bringing it down. Your arses will get burnt.
* * $CBYL Video Chart 06-03-16 * *
Link to Video - click here to watch the technical chart video
Followers
|
13
|
Posters
|
|
Posts (Today)
|
0
|
Posts (Total)
|
432
|
Created
|
04/24/15
|
Type
|
Free
|
Moderators |
KalVista is developing plasma kallikrein inhibitors for the treatment of hereditary angioedema (HAE) and diabetic macular edema (DME); indications where excessive plasma kallikrein activity is implicated, but where there remains substantial unmet clinical need. KalVista has built an expanding clinical and advanced preclinical product pipeline targeting multiple routes of administration to treat these diseases.
KalVista’s initial focus is on advancing a portfolio of orally delivered plasma kallikrein inhibitors for the treatment of HAE. The most advanced program, KVD818, is in Phase I clinical studies and additional molecules are expected to reach the clinic in 2017. KalVista’s most advanced program, an intravitreally administered plasma kallikrein inhibitor, has successfully completed its first-in-human study in patients with DME and is being prepared for Phase 2 clinical studies.
KalVista has an R&D team with an established track record in the pharmaceutical development of small molecule protease inhibitors, world-leading expertise in the role of plasma kallikrein in disease, and a management team with proven experience in bringing small molecules through the clinic to commercialization.
KalVista has offices in Cambridge, MA, USA and Salisbury, UK.
Volume | |
Day Range: | |
Bid Price | |
Ask Price | |
Last Trade Time: |